The Jefferies Group Reiterates “$108.00” Price Target for Stericycle Inc. (SRCL)

The Jefferies Group Reiterates “$108.00” Price Target for Stericycle Inc. (SRCL)

Jefferies Group set a $108.00 target price on Stericycle Inc. (NASDAQ:SRCL) in a research report released on Tuesday. The firm currently has a a buy rating on the stock.

A number of other research analysts have also commented on the company. Zacks Investment Research lowered Stericycle from a hold rating to a strong sell rating in a report on Friday, October 7th. Barrington Research reissued an outperform rating and set a $88.00 price objective (down previously from $100.00) on shares of Stericycle in a report on Wednesday, October 5th. Robert W. Baird lowered their price objective on Stericycle from $99.00 to $85.00 and set a neutral rating on the stock in a report on Friday, September 23rd. Wedbush lowered their price objective on Stericycle from $95.00 to $85.00 and set a neutral rating on the stock in a report on Thursday, September 22nd. Finally, Northcoast Research lowered Stericycle from a buy rating to a neutral rating in a report on Tuesday, September 20th. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and an average target price of $98.58.

Stericycle (NASDAQ:SRCL) opened at 79.73 on Tuesday. Stericycle has a 52 week low of $72.89 and a 52 week high of $128.94. The company has a market capitalization of $6.82 billion, a P/E ratio of 28.98 and a beta of 0.21. The company’s 50-day moving average price is $77.86 and its 200-day moving average price is $94.04.

Stericycle (NASDAQ:SRCL) last issued its quarterly earnings data on Thursday, October 27th. The company reported $1.24 EPS for the quarter, beating the Zacks’ consensus estimate of $1.17 by $0.07. The business had revenue of $890.10 million for the quarter, compared to analyst estimates of $899.87 million. Stericycle had a return on equity of 15.31% and a net margin of 7.52%. The firm’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.08 EPS. On average, equities analysts forecast that Stericycle will post $4.71 EPS for the current fiscal year.

In related news, EVP John P. Schetz sold 1,398 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $81.85, for a total transaction of $114,426.30. Following the completion of the transaction, the executive vice president now owns 1,088 shares in the company, valued at approximately $89,052.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Rodney F. Dammeyer sold 10,188 shares of the firm’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $85.50, for a total value of $871,074.00. Following the transaction, the director now owns 10,188 shares of the company’s stock, valued at approximately $871,074. The disclosure for this sale can be found here. Corporate insiders own 3.30% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Capstone Asset Management Co. increased its position in Stericycle by 0.3% in the third quarter. Capstone Asset Management Co. now owns 7,633 shares of the company’s stock valued at $612,000 after buying an additional 20 shares during the period. Parkside Financial Bank & Trust increased its position in Stericycle by 2.9% in the second quarter. Parkside Financial Bank & Trust now owns 1,432 shares of the company’s stock valued at $149,000 after buying an additional 41 shares during the period. Genesee Valley Trust Co. increased its position in Stericycle by 1.0% in the second quarter. Genesee Valley Trust Co. now owns 4,511 shares of the company’s stock valued at $470,000 after buying an additional 43 shares during the period. Spero Smith Investment Advisers Inc. OH increased its position in Stericycle by 0.3% in the second quarter. Spero Smith Investment Advisers Inc. OH now owns 16,883 shares of the company’s stock valued at $1,758,000 after buying an additional 50 shares during the period. Finally, Ameritas Investment Partners Inc. increased its position in Stericycle by 1.7% in the second quarter. Ameritas Investment Partners Inc. now owns 3,091 shares of the company’s stock valued at $322,000 after buying an additional 53 shares during the period. Institutional investors and hedge funds own 92.30% of the company’s stock.

Stericycle Company Profile

Related posts

Leave a Comment